menu
    • menu
    [{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"PARP","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ IDEAYA Biosciences ","highestDevelopmentStatusID":"1","companyTruncated":"Cancer Research \/ IDEAYA Biosciences "},{"orgOrder":0,"company":"Cancer Research","sponsor":"Touchlight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"TGL-100","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Touchlight","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Research \/ Touchlight"},{"orgOrder":0,"company":"Cancer Research","sponsor":"BioInvent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"BI-1206","moa":"Fc?RllB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Teon Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"TT-702","moa":"A2BR","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Aleta Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"ALETA-001","moa":"CD20","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Ideaya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"IDE161","moa":"PARG","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research Technology Ltd.","highestDevelopmentStatusID":"5","companyTruncated":"Cancer Research \/ Cancer Research Technology Ltd."},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"HTL0039732","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cancer Research \/ Cancer Research UK","highestDevelopmentStatusID":"4","companyTruncated":"Cancer Research \/ Cancer Research UK"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"AST-VAC2","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cancer Research \/ Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"Cancer Research \/ Cancer Research"},{"orgOrder":0,"company":"Cancer Research","sponsor":"Sosei Heptares","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cancer Research \/ Cancer Research","highestDevelopmentStatusID":"7","companyTruncated":"Cancer Research \/ Cancer Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Cancer Research

    Menu

    Cancer Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HTL0039732,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Sosei Heptares

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Can...

                            Details : HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.

                            Brand Name : HTL0039732

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2023

                            Lead Product(s) : HTL0039732,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Sosei Heptares

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AST-VAC2

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Lineage Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results with VAC2 for the Treatm...

                            Details : AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.

                            Brand Name : AST-VAC2

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 24, 2023

                            Lead Product(s) : AST-VAC2

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Lineage Cell Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HTL0039732

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy Candidate Into Clinical T...

                            Details : Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.

                            Brand Name : HTL0039732

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 22, 2022

                            Lead Product(s) : HTL0039732

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sosei Group Corporation

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IDE161

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Ideaya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Opt...

                            Details : Following the option exercise, IDEAYA holds exclusive worldwide license rights covering a broad class of PARG inhibitors. IDEAYA owns all commercial rights in IDE161, subject to economic obligations, worldwide license with Cancer Research UK and Universi...

                            Brand Name : IDE161

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 31, 2022

                            Lead Product(s) : IDE161

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Ideaya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALETA-001

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Aleta Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Aleta Biotherapeutics and Cancer Research UK Collaborate to Advance Blood Cancer Therapy Into the Clinic

                            Details : Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in ...

                            Brand Name : ALETA-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 23, 2021

                            Lead Product(s) : ALETA-001

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Aleta Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TT-702

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : Teon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Cancer Research UK and Teon Therapeutics Advance New First-in-Class Cancer Drug Into Clinical Trial

                            Details : The partnership focuses on Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist TT-702, for the treatment of multiplecancers including prostate and triple-negative breast.

                            Brand Name : TT-702

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 01, 2021

                            Lead Product(s) : TT-702

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : Teon Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI-1206,Rituximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : BioInvent

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioInvent Streamlines Agreement on Anti-Fcγ Rll B Antibody, BI-1206, Ahead of Phase I/II Data

                            Details : BioInvent is conducting a Phase I/II trial of BI-1206 in combination with rituximab to treat NHL. CRUK decided to end the trial being conducted in the UK after the single-agent part of the study. Both parties have agreed to restructure their agreement co...

                            Brand Name : BI-1206

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 11, 2021

                            Lead Product(s) : BI-1206,Rituximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : BioInvent

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGL-100

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cancer Research UK, University of Southampton and Touchlight Genetics Partner to Develop Head and Neck Cancer ...

                            Details : The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).

                            Brand Name : TGL-100

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 29, 2020

                            Lead Product(s) : TGL-100

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Touchlight

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Cancer Research

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Ideaya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration

                            Details : The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 11, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Ideaya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth